FibroBiologics, Inc. Common Stock

NASDAQ (USD): FibroBiologics, Inc. Common Stock (FBLG)

Last Price

2.49

Today's Change

+0.11 (4.62%)

Day's Change

2.30 - 2.49

Trading Volume

83,946

Profile
FBLG

Exchange:  Nasdaq Nasdaq

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Peter O'Heeron Mr. Peter O'Heeron

Full Time Employees:  10 10

IPO Date:  2024-02-01 2024-02-01

CIK:  0001958777 0001958777

ISIN:  US31573L1052 US31573L1052

CUSIP: 

Beta:  0.00 0.00

Last Dividend:  0.00 0.00

Dcf Diff:  2.23 2.23

Dcf:  0.26 0.26

Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Address

455 East Medical Center Boulevard,
Houston, 77598, US

281 651 5150

http://www.fibrobiologics.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment